Indivior Pharmaceuticals (INDV) Cash from Investing Activities (2024 - 2026)

Indivior Pharmaceuticals' Cash from Investing Activities history runs 3 years deep, the most recent figure standing at -$19.0 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 280.0% year-over-year to -$19.0 million in Q1 2026; TTM through Mar 2026 was -$80.0 million, a 305.13% decrease from a year earlier, with the FY2025 full-year figure at -$66.0 million, down 195.65% from the prior year.
• Cash from Investing Activities advanced to -$19.0 million in Q1 2026 per INDV's latest filing, from -$24.0 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $35.0 million in Q3 2024 and bottomed at -$24.0 million in Q4 2025.
• The 3-year median for Cash from Investing Activities is -$5.0 million (2025), against an average of -$1.8 million.
• Biggest YoY gain for Cash from Investing Activities was 120.0% in 2025; the steepest drop was 1800.0% in 2025.
• Year by year, Cash from Investing Activities stood at $8.0 million in 2024, then tumbled by 400.0% to -$24.0 million in 2025, then rose by 20.83% to -$19.0 million in 2026.
• Per Business Quant, the three latest INDV Cash from Investing Activities figures stand at -$19.0 million (Q1 2026), -$24.0 million (Q4 2025), and -$20.0 million (Q3 2025).